Literature DB >> 11912375

Neoinfundibulotomy for the management of symptomatic caliceal diverticula.

Brian K Auge1, Ravi Munver, John Kourambas, Glenn E Newman, Ning Z Wu, Glenn M Preminger.   

Abstract

PURPOSE: Direct percutaneous access provides effective treatment for complex caliceal diverticula. Yet, access into the diverticulum alone is usually tenuous and passage of a guide wire across a stenotic infundibulum is often impossible. An alternative technique is described which creates a "neoinfundibulum" to assist in the management of symptomatic caliceal diverticula.
MATERIALS AND METHODS: During a 6-year period 22 patients with symptomatic caliceal diverticula were treated via a percutaneous approach, of whom 21 had calculi within the diverticula. After accessing the diverticulum directly, it was impossible to pass a guide wire through the stenotic infundibulum in 18 (82%) patients, prompting advancement of the access needle through the diverticular wall into the renal pelvis. Once secure access was established, balloon dilation was performed to 30Fr to create the "neoinfundibulum." Percutaneous ultrasonic lithotripsy was performed in the usual fashion. A 22Fr Councill catheter was placed to keep the infundibular tract open for 5 to 7 days to allow complete epithelialization and drainage. Stone-free, symptom-free and complication rates were assessed.
RESULTS: Pain, recurrent urinary tract infections and hematuria were the presenting complaints in the subgroup of patients undergoing "neoinfundibulotomy." Average stone burden was 11.7 x 12 mm. and average hospital stay was 2.8 days. Of the patients 94% were symptom-free at 6-week followup, and 80% were stone-free on followup excretory urography. The remaining patients had residual stone fragments less than 3 mm. in diameter. Complications related to access were identified in 2 patients who sustained a pneumothorax after a supra-11th rib access, which was successfully managed with tube thoracostomy.
CONCLUSIONS: Percutaneous management of complex caliceal diverticula provides a safe and effective option for symptomatic patients. When the stenotic infundibulum cannot be traversed with a guide wire, creation of a new infundibulum offers a secure alternative for accessing the collecting system, while providing equally effective results.

Entities:  

Mesh:

Year:  2002        PMID: 11912375

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  Calyceal diverticula: a comprehensive review.

Authors:  Nikhil Waingankar; Samih Hayek; Arthur D Smith; Zeph Okeke
Journal:  Rev Urol       Date:  2014

Review 2.  Anatomy and Physiology of the Urinary Tract: Relation to Host Defense and Microbial Infection.

Authors:  Duane R Hickling; Tung-Tien Sun; Xue-Ru Wu
Journal:  Microbiol Spectr       Date:  2015-08

3.  Percutaneous nephroscopic surgery.

Authors:  Tae-Kon Hwang
Journal:  Korean J Urol       Date:  2010-05-19

4.  Percutaneous management of caliceal diverticuli.

Authors:  Amy E Krambeck; James E Lingeman
Journal:  J Endourol       Date:  2009-10       Impact factor: 2.942

5.  Management of calyceal diverticular calculi: a comparison of percutaneous nephrolithotomy and flexible ureterorenoscopy.

Authors:  Okan Bas; Ekrem Ozyuvali; Yasin Aydogmus; Nevzat Can Sener; Onur Dede; Serhat Ozgun; Fatih Hizli; Cagri Senocak; Omer Faruk Bozkurt; Halil Basar; Abdurrahim Imamoglu
Journal:  Urolithiasis       Date:  2014-09-24       Impact factor: 3.436

6.  Is retrograde flexible nephrolithotripsy feasible for calyceal diverticular stone?

Authors:  Bulent Erkurt; Murat Can Kiremit; Bulent Altay; Vahit Guzelburc; Mustafa Soytas; Firat Erdogan; Cem Cahit Barisik; Selami Albayrak
Journal:  Urolithiasis       Date:  2014-06-12       Impact factor: 3.436

7.  Retrospective Analysis of Ultrasound-guided Flexible Ureteroscopy in the Management of Calyceal Diverticular Calculi.

Authors:  Ji-Qing Zhang; Yong Wang; Jun-Hui Zhang; Xiao-Dong Zhang; Nian-Zeng Xing
Journal:  Chin Med J (Engl)       Date:  2016-09-05       Impact factor: 2.628

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.